Welcome to our dedicated page for United Airlines Holdings SEC filings (Ticker: UAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Fuel hedging footnotes on page 120, leased-aircraft obligations buried in Exhibit 21, and MileagePlus revenue recognition scattered across multiple sections—United Airlines Holdings’ SEC documents can feel overwhelming. Finding the capacity guidance you need or isolating union labor liabilities in the 10-K is time-consuming, even for aviation professionals.
Stock Titan solves that problem. Our AI-powered summaries turn United Airlines annual report 10-K simplified into plain English, flagging where jet-fuel costs hit margins and how deferred loyalty revenue flows to cash. You’ll see United Airlines quarterly earnings report 10-Q filing highlights seconds after EDGAR posts, plus instant alerts when an 8-K lands—United Airlines 8-K material events explained before the market digests them. Need governance details? We link directly to the latest United Airlines proxy statement executive compensation so you can compare CEO pay against peer carriers without digging through appendices.
Whether you’re tracking United Airlines insider trading Form 4 transactions or want United Airlines Form 4 insider transactions real-time push notifications, our platform keeps you ahead. Use cases include:
- Spotting United Airlines executive stock transactions Form 4 ahead of earnings
- Running quick United Airlines earnings report filing analysis for PRASM and ASM trends
- Understanding United Airlines SEC documents with AI to evaluate aircraft purchase commitments
In short, United Airlines SEC filings explained simply—with real-time coverage of every form and AI guidance that turns airline accounting into actionable insight.
United Airlines Holdings, Inc. (UAL) has filed a Form 4 disclosing an insider transaction by Director Walter Isaacson.
- Transaction date: 06/30/2025
- Securities involved: 502.89 derivative share units acquired at $0 cost under the company’s 2006 Director Equity Incentive Plan (DEIP).
- Conversion ratio: 1 share unit = 1 share of common stock.
- Settlement timing: Units convert to common stock after the director’s separation from service, per DEIP terms.
- Post-transaction holdings: Isaacson now beneficially owns 21,058.91 share units, held directly.
The filing represents a routine deferral of quarterly director retainer fees rather than an open-market purchase or sale. No non-derivative common stock transactions were reported. The disclosure is dated 07/02/2025 and contains no price-sensitive information beyond the incremental increase in deferred equity.
United Airlines Holdings, Inc. (UAL) has filed a Form 4 disclosing an insider transaction by Director Walter Isaacson.
- Transaction date: 06/30/2025
- Securities involved: 502.89 derivative share units acquired at $0 cost under the company’s 2006 Director Equity Incentive Plan (DEIP).
- Conversion ratio: 1 share unit = 1 share of common stock.
- Settlement timing: Units convert to common stock after the director’s separation from service, per DEIP terms.
- Post-transaction holdings: Isaacson now beneficially owns 21,058.91 share units, held directly.
The filing represents a routine deferral of quarterly director retainer fees rather than an open-market purchase or sale. No non-derivative common stock transactions were reported. The disclosure is dated 07/02/2025 and contains no price-sensitive information beyond the incremental increase in deferred equity.
United Airlines Holdings, Inc. (UAL) has filed a Form 4 disclosing an insider transaction by Director Walter Isaacson.
- Transaction date: 06/30/2025
- Securities involved: 502.89 derivative share units acquired at $0 cost under the company’s 2006 Director Equity Incentive Plan (DEIP).
- Conversion ratio: 1 share unit = 1 share of common stock.
- Settlement timing: Units convert to common stock after the director’s separation from service, per DEIP terms.
- Post-transaction holdings: Isaacson now beneficially owns 21,058.91 share units, held directly.
The filing represents a routine deferral of quarterly director retainer fees rather than an open-market purchase or sale. No non-derivative common stock transactions were reported. The disclosure is dated 07/02/2025 and contains no price-sensitive information beyond the incremental increase in deferred equity.
On July 1, 2025, Seres Therapeutics (MCRB) filed a Form 4 indicating that non-employee director Claire Fraser received a stock option for 6,452 shares of common stock at an exercise price of $10.71. The option expires on July 1, 2035 and vests in four equal quarterly installments beginning October 1, 2025 and ending July 1, 2026, with the final tranche accelerated if the 2026 annual shareholder meeting occurs earlier. Following the grant, Fraser beneficially owns 6,452 derivative securities; no open-market acquisitions or sales of common stock were reported. The transaction is routine director compensation, non-cash in nature, and does not materially affect Seres Therapeutics’ share count or cash position.
On July 1, 2025, Seres Therapeutics (MCRB) filed a Form 4 indicating that non-employee director Claire Fraser received a stock option for 6,452 shares of common stock at an exercise price of $10.71. The option expires on July 1, 2035 and vests in four equal quarterly installments beginning October 1, 2025 and ending July 1, 2026, with the final tranche accelerated if the 2026 annual shareholder meeting occurs earlier. Following the grant, Fraser beneficially owns 6,452 derivative securities; no open-market acquisitions or sales of common stock were reported. The transaction is routine director compensation, non-cash in nature, and does not materially affect Seres Therapeutics’ share count or cash position.